Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (Policlinico Gemelli)
- Development stage
- Unknown
- Lead developer
- Policlinico Gemelli
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal microbiota transplantation (FMT) is an investigational microbial therapy being evaluated by the Fondazione Policlinico Universitario Agostino Gemelli IRCCS for the treatment of mild-to-moderate ulcerative colitis. The approach utilizes "superdonor" stool—samples from healthy individuals identified as having high microbial diversity and a history of inducing clinical remission in recipients. By transferring a complex community of commensal bacteria, FMT aims to correct intestinal dysbiosis, restore the production of anti-inflammatory metabolites like short-chain fatty acids, and modulate the host's mucosal immune system to reduce colonic inflammation. In clinical trials conducted by the Fondazione Gemelli, the therapy is typically administered via colonoscopy followed by a series of enemas to ensure adequate colonization of the recipient's gut.
- Other names
- FMTsuperdonor fecal microbiota transplantationfecal bacteriotherapysuperdonor FMT
Beyond the preview
Go deeper on fecal microbiota transplantation (Policlinico Gemelli).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (Policlinico Gemelli).